French medical devices company Biocorp has entered an agreement with Novo Nordisk to develop and distribute a Mallya smart add-on device for the latter’s FlexTouch pen used by diabetes patients.
A Bluetooth-enabled smart add-on device for insulin pen injectors, Biocorp’s Mallya is designed to gather the dose and time of individual injection and send the real-time data to a companion software.
Go deeper with GlobalData
The device could aid diabetes patients in maintaining a consistent dose log, Biocorp noted.
Novo Nordisk provides most of its insulins with the FlexTouch pen, which is also part of its launch plan for all new insulins.
Under the latest partnership, a specific Mallya version will be created for the insulin delivery pen.
FlexTouch is said to be the first prefilled insulin delivery device without push-button extension.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBased on the pen’s dosing mechanism, the push button does not extend at any dose and enables insulin administration by pressing the low injection force button.
Biocorp added that the current Mallya device needs to be redesigned to cater to this mechanism while retaining its accuracy and reliability for the user.
The new Mallya will be connected directly to the disposable pre-filled FlexTouch pen and enable efficient dose logging for patients and their healthcare providers, which could lead to more individualised treatments.
Novo Nordisk digital health vice-president Søren Smed Østergaard said: “This collaboration demonstrates our commitment to making diabetes management easier by giving people access to data on medication usage behaviour which is known to potentially result in improved patient outcomes.”
As part of the agreement, Biocorp is eligible for an upfront payment as well as various milestone payments.
Novo Nordisk intends to distribute the smart device in some countries and Biocorp anticipates boosting production volumes from next year.
Earlier this month, Biocorp signed a partnership deal with Merck to develop and market a specific version of the Mallya device for use in the field of Human Growth Hormone (HGH).
